×
About 9,351 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  4,223 results

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma...
https://doi.org/10.1111/bjh.17513
British Journal of Haematology; Rampotas A, Wilson MR et. al.

May 7th, 2021 - Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of att...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

In like a lamb; out like a lion: Marching CAR-T cells towards enhanced efficacy in ALL.
https://doi.org/10.1158/1535-7163.MCT-20-1089
Molecular Cancer Therapeutics; Safarzadeh Kozani P, Safarzadeh Kozani P et. al.

Apr 27th, 2021 - Combining synthetic biology with adoptive T cell transfer has led to promising advances in the treatment of relapsed refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL)....

Transcriptome integration analysis and specific diagnosis model construction for Hodgki...
https://doi.org/10.18632/aging.202882
Aging Li WX, Dai SX et. al.

Apr 22nd, 2021 - Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic model...

CAR-T cell persistence in the treatment of leukemia and lymphoma.
https://doi.org/10.1080/10428194.2021.1913146
Leukemia & Lymphoma; Gupta A, Gill S

Apr 19th, 2021 - Chimeric antigen receptor (CAR) T cells have emerged as a powerful therapeutic modality for cancer. Following encouraging clinical results, autologous anti-CD19 CAR-T cells first secured regulatory approval from the U.S. Food and Drug Administrati...

see more →

Guidelines  13 results

FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson,J.,et al

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...

Guideline for the management of mantle cell lymphoma.
https://doi.org/10.1111/bjh.15283
British Journal of Haematology; McKay P, Leach M et. al.

May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

see more →

Drugs  25 results see all →

Clinicaltrials.gov  4,589 results

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma...
https://doi.org/10.1111/bjh.17513
British Journal of Haematology; Rampotas A, Wilson MR et. al.

May 7th, 2021 - Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of att...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

In like a lamb; out like a lion: Marching CAR-T cells towards enhanced efficacy in ALL.
https://doi.org/10.1158/1535-7163.MCT-20-1089
Molecular Cancer Therapeutics; Safarzadeh Kozani P, Safarzadeh Kozani P et. al.

Apr 27th, 2021 - Combining synthetic biology with adoptive T cell transfer has led to promising advances in the treatment of relapsed refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL)....

Transcriptome integration analysis and specific diagnosis model construction for Hodgki...
https://doi.org/10.18632/aging.202882
Aging Li WX, Dai SX et. al.

Apr 22nd, 2021 - Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic model...

CAR-T cell persistence in the treatment of leukemia and lymphoma.
https://doi.org/10.1080/10428194.2021.1913146
Leukemia & Lymphoma; Gupta A, Gill S

Apr 19th, 2021 - Chimeric antigen receptor (CAR) T cells have emerged as a powerful therapeutic modality for cancer. Following encouraging clinical results, autologous anti-CD19 CAR-T cells first secured regulatory approval from the U.S. Food and Drug Administrati...

see more →

News  501 results

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.staging.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
https://www.staging.medscape.com/viewarticle/937175

Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...

see more →